ImmunityBio has partnered with Biopharma and Cigalah Healthcare to commercialise ANKTIVA® (nogapendekin alfa inbakicept) in Saudi Arabia for bladder and lung cancer treatment.

• Collaboration: Biopharma and Cigalah Healthcare will support local commercialisation and distribution in Saudi Arabia.
• Indications: The launch covers ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer and in combination with a checkpoint inhibitor for metastatic non-small cell lung cancer.
• Regulatory Status: The therapy has received registration approval from the Saudi Food and Drug Authority.

This summary is based on a report published by BioSpectrum Asia.